Beyond antibody-mediated rejection: Hyperacute lung rejection as a paradigm for dysregulated inflammation

Bao H. Nguyen, Egon Zwets, Carsten Schroeder, Richard N. Pierson, Agnes M. Azimzadeh

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

The use of animal organs for transplantation in humans is seen as a potential solution to the short supply of human donor organs available for clinical transplantation. However, to develop this therapeutic option as clinical reality will require surmounting formidable obstacles. The primary immunologic barrier to pig-to-human xenotransplantation is hyperacute rejection (HAR), a phenomenon previously characterized as resulting from antibody binding and complement activation. This article will first review recent progress in the development of specific strategies to overcome hyperacute lung rejection (HALR), through production of genetically engineered pig organs, modification of the host innate immunity and control of antibody and complement. Additional therapeutic targets identified in HALR are reviewed, with particular emphasis on recent studies describing a critical role for the coagulation cascade in HAR.

Original languageEnglish (US)
Pages (from-to)255-269
Number of pages15
JournalCurrent Drug Targets - Cardiovascular and Haematological Disorders
Volume5
Issue number3
DOIs
StatePublished - Jun 1 2005

Fingerprint

Inflammation
Lung
Antibodies
Swine
Animal Structures
Heterologous Transplantation
Complement Activation
Organ Transplantation
Innate Immunity
Transplantation
Tissue Donors
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Hematology
  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Beyond antibody-mediated rejection : Hyperacute lung rejection as a paradigm for dysregulated inflammation. / Nguyen, Bao H.; Zwets, Egon; Schroeder, Carsten; Pierson, Richard N.; Azimzadeh, Agnes M.

In: Current Drug Targets - Cardiovascular and Haematological Disorders, Vol. 5, No. 3, 01.06.2005, p. 255-269.

Research output: Contribution to journalReview article

Nguyen, Bao H. ; Zwets, Egon ; Schroeder, Carsten ; Pierson, Richard N. ; Azimzadeh, Agnes M. / Beyond antibody-mediated rejection : Hyperacute lung rejection as a paradigm for dysregulated inflammation. In: Current Drug Targets - Cardiovascular and Haematological Disorders. 2005 ; Vol. 5, No. 3. pp. 255-269.
@article{0199ebe1b15e4c7184c732fadd8199fb,
title = "Beyond antibody-mediated rejection: Hyperacute lung rejection as a paradigm for dysregulated inflammation",
abstract = "The use of animal organs for transplantation in humans is seen as a potential solution to the short supply of human donor organs available for clinical transplantation. However, to develop this therapeutic option as clinical reality will require surmounting formidable obstacles. The primary immunologic barrier to pig-to-human xenotransplantation is hyperacute rejection (HAR), a phenomenon previously characterized as resulting from antibody binding and complement activation. This article will first review recent progress in the development of specific strategies to overcome hyperacute lung rejection (HALR), through production of genetically engineered pig organs, modification of the host innate immunity and control of antibody and complement. Additional therapeutic targets identified in HALR are reviewed, with particular emphasis on recent studies describing a critical role for the coagulation cascade in HAR.",
author = "Nguyen, {Bao H.} and Egon Zwets and Carsten Schroeder and Pierson, {Richard N.} and Azimzadeh, {Agnes M.}",
year = "2005",
month = "6",
day = "1",
doi = "10.2174/1568006054064753",
language = "English (US)",
volume = "5",
pages = "255--269",
journal = "Cardiovascular and Hematological Disorders - Drug Targets",
issn = "1871-529X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Beyond antibody-mediated rejection

T2 - Hyperacute lung rejection as a paradigm for dysregulated inflammation

AU - Nguyen, Bao H.

AU - Zwets, Egon

AU - Schroeder, Carsten

AU - Pierson, Richard N.

AU - Azimzadeh, Agnes M.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - The use of animal organs for transplantation in humans is seen as a potential solution to the short supply of human donor organs available for clinical transplantation. However, to develop this therapeutic option as clinical reality will require surmounting formidable obstacles. The primary immunologic barrier to pig-to-human xenotransplantation is hyperacute rejection (HAR), a phenomenon previously characterized as resulting from antibody binding and complement activation. This article will first review recent progress in the development of specific strategies to overcome hyperacute lung rejection (HALR), through production of genetically engineered pig organs, modification of the host innate immunity and control of antibody and complement. Additional therapeutic targets identified in HALR are reviewed, with particular emphasis on recent studies describing a critical role for the coagulation cascade in HAR.

AB - The use of animal organs for transplantation in humans is seen as a potential solution to the short supply of human donor organs available for clinical transplantation. However, to develop this therapeutic option as clinical reality will require surmounting formidable obstacles. The primary immunologic barrier to pig-to-human xenotransplantation is hyperacute rejection (HAR), a phenomenon previously characterized as resulting from antibody binding and complement activation. This article will first review recent progress in the development of specific strategies to overcome hyperacute lung rejection (HALR), through production of genetically engineered pig organs, modification of the host innate immunity and control of antibody and complement. Additional therapeutic targets identified in HALR are reviewed, with particular emphasis on recent studies describing a critical role for the coagulation cascade in HAR.

UR - http://www.scopus.com/inward/record.url?scp=21044452660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044452660&partnerID=8YFLogxK

U2 - 10.2174/1568006054064753

DO - 10.2174/1568006054064753

M3 - Review article

C2 - 15975038

AN - SCOPUS:21044452660

VL - 5

SP - 255

EP - 269

JO - Cardiovascular and Hematological Disorders - Drug Targets

JF - Cardiovascular and Hematological Disorders - Drug Targets

SN - 1871-529X

IS - 3

ER -